All News
Biologics, #RA and Risk of skin CA (NMSC) is complex.
- RA alone is a risk for NMSC
49K study of ABA & NMSC ;
- In RCTs, risk same w/ ABA & PBO
- Registries & Claims data: equal w/ ABA, csDMARDs. b/tsDMARDs
- Pooled obs data shows slight ABA risk https://t.co/tp6F0cJWug https://t.co/u6UdAUZqoc
Dr. John Cush RheumNow ( View Tweet)
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN Variants
A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved to be effective and without potentially allergic lung reactions.
Read Article
New download available, titled "Dealing with Infections"
https://t.co/hsOuJoFokg https://t.co/G3MZ9BQo0X
Dr. John Cush RheumNow ( View Tweet)
FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/4f6Ew5KGmg https://t.co/SldJ6MXMw7 https://t.co/KfCww7doef
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/4f6Ew5KGmg https://t.co/SldJ6MXMw7 https://t.co/KfCww7doef
Dr. John Cush RheumNow ( View Tweet)
Analysis of German RABBIT registry did not show more MACE events in pts w/ JAK inhibitors compared to other DMARDs. 154 MACE w/ 14203 Rx episodes (21218 Pt-Yrs). IRs were 0.68 JAKi, 0.62 TNFi, 0.76 bdMARDs and 0.95 csDMARDs; higher in CV risk pts https://t.co/luUK9M9IM9 https://t.co/z8lxjWscCR
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0%
HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i
More reactivation if pt is HBsAb- (OR=4.56) https://t.co/V60nkUSpjj https://t.co/jnZKnY0Zuk
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
https://t.co/oTGm16k6Uo https://t.co/tSysmriP7q https://t.co/TIZc8rxwxM
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
https://t.co/oTGm16k6Uo https://t.co/tSysmriP7q https://t.co/TIZc8rxwxM
Links:
Dr. John Cush RheumNow ( View Tweet)
Late Should Not Be Less (11.3.2023)
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Read Article
FDA has approved another ustekinumab biosimilar (Wezlana) as being interchangeable for use in adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. https://t.co/zbQKjmKgZh https://t.co/UuTDRgCBIV
Dr. John Cush RheumNow ( View Tweet)
Ph 3 360 pt RCT of sarilumab in #GCA was terminated early (COVID). 83 pts Rx'd, only 35%(29) completed. Sustained remission @wk 52:
- SAR 200: 6/13
- SAR 150: 3/7
- PBO: 0/6
All had 26wk GC taper
Sm sample size & COVID ruined RCT interpretation https://t.co/axOvJGpUti #PMR https://t.co/Xpabxn1IjZ
Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Biosimilars?
Dr. Cush reviews RheumNow's top entries the #PMR Campaign, news, journal reports and regulatory actions.
https://t.co/BkKFbv0I64 https://t.co/EABeZxCKYZ
Dr. John Cush RheumNow ( View Tweet)
Choosing steroid sparing therapies in PMR
Despite the official recognition of PMR as a distinct disease more than 60 years ago, patients with PMR are still largely treated with steroids (glucocorticoids, mostly prednisone). The persistent broad use of glucocorticoids in PMR is related to their quick initial efficacy in the majority of patients with PMR, their low price and the lack of alternative treatments and paucity of glucocorticoid-sparing treatments.
Read Article
Subcutaneous Remsima, an infliximab biosimilar, has been FDA. Celltrion has rebranded this as Zymfentra, for maintenance therapy in adults with moderately to severely active Ulcerative colitis and Crohn's disease following (after giving IV infliximab) https://t.co/3hb5Z7L9uw https://t.co/4gvSurl1nM
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
Read Article
Subcutaneous Biosimilars? (10.27.2023)
Dr. Jack Cush reviews RheumNow's top entries the PMR Campaign, news, journal reports and regulatory actions.
Read Article
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today!
https://t.co/7OsdPYWukv https://t.co/QoCxR04bJD
Links:
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Bimekizumab for Plaque Psoriasis
UCB announced today that the FDA has approved bimekizumab-bkzx (Bimzelx)) for the treatment of moderate to severe plaque psoriasis in adults who needing systemic therapy or phototherapy.
https://t.co/BqeSAAxtQb https://t.co/LFjzkmAC5w
Dr. John Cush RheumNow ( View Tweet)
Bimekizumab (Bimelex), a dual IL-17A/F inhibitor, is FDA approved for u Treatment of Adults with Moderate to Severe Plaque Psoriasis https://t.co/Eo4LMaTHxn https://t.co/abzlThasEN
Dr. John Cush RheumNow ( View Tweet)